Genmab AS Total Assets
Genmab AS total assets. Based on the latest financial reports, Genmab AS (GMAB) holds total assets worth $12.84 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Genmab AS worth for the company's overall valuation and market capitalisation.
Total Assets of Genmab AS (2002–2025)
Total assets of Genmab AS from 2002 to 2025. This chart illustrates how Genmab AS's total assets have evolved over time, based on quarterly financial data. See Genmab AS stock quote for real-time trading data and today's change.
Genmab AS - Asset Composition Analysis
Genmab AS Total Assets Breakdown (December 2025)
Genmab AS total assets breakdown as of December 2025. Genmab AS's total assets of $12.84 Billion consist of 22.4% current assets and 77.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $1.15 Billion | 9.0% |
| Inventory | $17.96 Million | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.10 Billion | 70.9% |
| Goodwill | $354.19 Million | 2.8% |
Asset Composition Trend (2002–2025)
This chart illustrates how Genmab AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Genmab AS current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genmab AS's current assets represent 22.4% of total assets in 2025, a decrease from 89.6% in 2002.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 16.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 4.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 70.9% of total assets.
Genmab AS Competitors by Total Assets
Key competitors of Genmab AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Genmab AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 5.25 | 15.42 |
| Quick Ratio | 2.01 | 5.24 | 15.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.45 Billion | $22.55 Billion | $18.64 Billion |
Genmab AS - Advanced Valuation Insights
This section examines the relationship between Genmab AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.92 |
| Latest Market Cap to Assets Ratio | 1.26 |
| Asset Growth Rate (YoY) | -72.0% |
| Total Assets | $12.84 Billion |
| Market Capitalization | $16.23 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Genmab AS's assets above their book value (1.26x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Genmab AS's assets decreased by 72.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genmab AS (2002–2025)
The table below shows the annual total assets of Genmab AS from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.84 Billion | -71.96% |
| 2024-12-31 | $45.81 Billion | +29.82% |
| 2023-12-31 | $35.29 Billion | +17.17% |
| 2022-12-31 | $30.12 Billion | +22.30% |
| 2021-12-31 | $24.63 Billion | +16.48% |
| 2020-12-31 | $21.14 Billion | +39.61% |
| 2019-12-31 | $15.14 Billion | +78.99% |
| 2018-12-31 | $8.46 Billion | +28.14% |
| 2017-12-31 | $6.60 Billion | +26.05% |
| 2016-12-31 | $5.24 Billion | +34.23% |
| 2015-12-31 | $3.90 Billion | +36.13% |
| 2014-12-31 | $2.87 Billion | +65.56% |
| 2013-12-31 | $1.73 Billion | +2.28% |
| 2012-12-31 | $1.69 Billion | +8.21% |
| 2011-12-31 | $1.56 Billion | -36.96% |
| 2010-12-31 | $2.48 Billion | +11.71% |
| 2009-12-31 | $2.22 Billion | -31.83% |
| 2008-12-31 | $3.26 Billion | -17.68% |
| 2007-12-31 | $3.96 Billion | +119.37% |
| 2006-12-31 | $1.80 Billion | +31.68% |
| 2005-12-31 | $1.37 Billion | +7.75% |
| 2004-12-31 | $1.27 Billion | +7.78% |
| 2003-12-31 | $1.18 Billion | -25.46% |
| 2002-12-31 | $1.58 Billion | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more